Antagonist of platelet-activating factor prevents prostaglandin E2 induced ocular hypertension in rabbits.
Topical application of 250 micrograms of platelet activating factor (PAF) or 5 micrograms of prostaglandin E2 (PGE2) to the rabbit's eye is followed by a rise in intraocular pressure (IOP). The occurrence of PAF in the anterior chamber is held responsible for this effect, as appears from the observed concentrations of PAF in a ng/ml-range in the aqueous humor and from the inhibition in the rise of IOP by systemic pretreatment of rabbits with the PAF-antagonist BN 52021 (10 mg/kg). Corneal and conjunctival edema, occurring after application of PAF, are not influenced by BN 52021. Thus, these effects may be ascribed to the non-specific membrane pertubant action of the high local concentration of PAF, necessary to achieve effective concentrations of PAF in the anterior chamber.
Jager
G V
GV
Department of Ophthalmology, University Hospital, Leiden, The Netherlands.
van Delft
J L
JL
van Haeringen
N J
NJ
Verbeij
N L
NL
Braquet
P
P
D000818:Animals; D015232:Dinoprostone / Q000494:pharmacology*; D004224:Diterpenes; D004305:Dose-Response Relationship, Drug; D046934:Ginkgolides; D007429:Intraocular Pressure / Q000187:drug effects*; D007700:Kinetics; D007783:Lactones / Q000494:pharmacology*; D008297:Male; D010972:Platelet Activating Factor / Q000008:administration & dosage / Q000037:antagonists & inhibitors* / Q000494:pharmacology; D011817:Rabbits
D004224:Diterpenes; D046934:Ginkgolides; D007783:Lactones; D010972:Platelet Activating Factor; C045856:ginkgolide B; D015232:Dinoprostone